Stay informed with the latest advances in colorectal health, AI technology, and patient care.
ColoWatch® has been approved as a member of the NVIDIA Inception program, a global startup program designed to help companies build faster and grow through access to technical resources, training, partner offers, and go-to-market support.
NewsColoWatch® has been approved as a member of the NVIDIA Inception program, a global startup program designed to help companies build faster and grow through access to technical resources, training, partner offers, and go-to-market support.
NewsA Boston Medical Center radiologist is sounding the alarm on one of medicine's most underutilized tools: virtual colonoscopy. Despite strong evidence and a patient-friendly profile, it accounts for just 2.2% of colorectal cancer screenings. Here's why that gap needs to close.
NewsNew findings from the Radiological Society of North America add to a growing body of evidence that CT colonography isn't just a convenience — it's a clinically superior screening option for many patients. Here's what the research says, and why it matters for the millions of Americans still avoiding colorectal cancer screening.
Press ReleaseColoWatch® announces the appointment of Dr. Cecelia Brewington — System and Academic Chair of Radiology at Ochsner Health, Fellow of the American College of Radiology, and a driving force behind the landmark 2025 Medicare coverage decision for virtual colonoscopy — as a Founding Clinical Advisor.
ResearchA peer-reviewed cost-effectiveness analysis published in Radiology demonstrates that virtual colonoscopy (CT colonography) dominates over multitarget stool DNA testing (Cologuard) — delivering superior cancer prevention while actually saving money. The study, led by ColoWatch® Founding Clinical Advisor Dr. Perry J. Pickhardt, found virtual colonoscopy reduces colorectal cancer incidence by 70–75% compared to just 59% for Cologuard, at lower overall cost.
NewsFollowing the death of actor James Van Der Beek at 48 from colon cancer, the shortcomings of current colorectal cancer screening guidelines deserve scrutiny. The American Cancer Society recommends screening begin at age 45 via traditional colonoscopy or stool testing — but both approaches fall short. Colonoscopy misses up to 25% of significant polyps, causes over 1,100 direct deaths and 64,000 complications annually in the U.S., and the age-45 threshold still misses more than half of cancers in the under-50 group where rates are climbing fastest. Stool tests, while safe, are poor at catching precursor polyps. A superior alternative — virtual colonoscopy (CT colonography) — detects 95% of cancers and 94% of key polyps with zero reported deaths worldwide in over 25 years of use. It also catches unsuspected non-colon cancers in 1 of every 300 exams. Yet it remains largely sidelined in American healthcare guidelines. As colorectal cancer rates surge among younger adults, virtual colonoscopy offers a safer, more accurate, and more cost-effective path to screening that could save thousands of lives.
NewsA groundbreaking study reveals heavy lifetime alcohol use increases colorectal cancer risk by up to 91%. With CRC now the #1 cancer killer of adults under 50, this research underscores why accessible, non-invasive screening options are more critical than ever.
NewsNew research confirms what we've been warning about: colorectal cancer has become the deadliest cancer for people under 50. The solution lies in accessible, safe screening.
NewsNew partnership to expand the availability of virtual colonoscopy for the early detection of colon and rectal cancer.
TechnologyVirtual Colonoscopy is performed with rapid, ultra-low-dose CT scanning. It is far safer, more accurate for finding concerning polyps, and less expensive than traditional colonoscopy.